# 2026-12622: FDA Offers New Tips for Proving Drug Effectiveness 2026-12622, Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products; Revised Draft Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-06-24, effective Submit either electronic or written comments on the draft guidance by September 22, 2026 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.; PRIA reads it as touching household money (as of 2026-07-01). - Canonical: https://policyrisk.com/federal-register/2026-12622 - As of: 2026-07-01 - Plain-text twin of the page above; the HTML and this file carry the same facts. ## Facts - Document number: 2026-12622 - Title: Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products; Revised Draft Guidance for Industry; Availability - Type: Notice - Agencies: Health and Human Services Department; Food and Drug Administration - Citation: 91 FR 37994 - Published: 2026-06-24 - Effective: Submit either electronic or written comments on the draft guidance by September 22, 2026 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. - Comments close: 2026-09-22 - Significant: no - Touches household money: yes - Regulation identifier numbers: none - Last updated: 2026-07-01 ## In one line FDA Offers New Tips for Proving Drug Effectiveness ## Summary The FDA just released a new draft guide to help drug makers prove their medicines really work, using smarter and faster science. This update affects companies developing human drugs and biological products, aiming to save time and money by allowing strong evidence from just one good clinical study plus extra proof. Comments on this draft are open until September 22, 2026, so industry folks have a chance to weigh in before it becomes final. ## Abstract The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a revised draft guidance for industry titled "Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products." FDA has revised and is reissuing this draft guidance in response to public comments and to changes in drug development by focusing on generating rigorous scientific evidence in the most efficient manner. Advances in our understanding of biological processes and the increasing availability of high-quality data have transformed the evidentiary landscape for drug development. Given these advances, the draft guidance discusses the many factors that can impact the strength of evidence of effectiveness for a drug and clarifies how sponsors can rely on one adequate and well-controlled clinical investigation with confirmatory evidence to satisfy the substantial evidence of effectiveness standard. When final, this guidance will replace the 1998 guidance titled "Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products." ## Effects PRIA read - One Trial Plus Confirmatory Evidence: benefit, medium. If you develop human drugs or biological products, FDA's revised draft guidance clarifies that sponsors can satisfy the substantial evidence of effectiveness standard by relying on one adequate and well-controlled clinical investigation plus confirmatory evidence. The guidance focuses on generating… - Flexibility for Critical and Rare Diseases: benefit, medium. The revised draft guidance retains discussion of regulatory flexibility in certain critical settings, including programs for diseases that lack effective treatments and rare diseases. FDA notes it may accept somewhat greater uncertainty about effectiveness in those settings when balanced against th… - No New FDA Paperwork Burden: benefit, low. FDA states the draft guidance contains no new collections of information and instead refers to previously approved collections under OMB control numbers 0910-0014, 0910-0001, and 0910-0338. That means the guidance itself does not impose new FDA paperwork or information-collection requirements on sp… - 1998 Guidance To Be Withdrawn: mixed, medium. FDA plans to withdraw the 1998 guidance titled 'Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products' after finalizing this revised draft guidance, so the Agency's recommended approaches for meeting the substantial evidence standard will change. Sponsors should review… - Public Comment Window Closes Sept 22, 2026: benefit, low. FDA is accepting electronic or written comments on this revised draft guidance through September 22, 2026 (Docket No. FDA-2019-D-4964). Industry stakeholders can submit comments at https://www.regulations.gov to have their views considered before FDA begins work on the final guidance. ## Related documents - [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11 - [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13 - [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29 - [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25 - [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27 - [2026-20727](https://policyrisk.com/federal-register/2026-20727): Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorgani…, 2026-10-09 ## Sources - [2026-12622 on federalregister.gov](https://www.federalregister.gov/documents/2026/06/24/2026-12622/demonstrating-substantial-evidence-of-effectiveness-for-human-drug-and-biological-products-revised) - [2026-12622 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-06-24/pdf/2026-12622.pdf) ## Related - [Previous: 2026-12621, Expedited Investigational New Drug Pilot Program; Request for Information](https://policyrisk.com/federal-register/2026-12621) - [Next: 2026-12623, Rockies Express Pipeline LLC, Cheyenne Connector, LLC, East Cheyenne Gas Storag…](https://policyrisk.com/federal-register/2026-12623) - [All Federal Register documents](https://policyrisk.com/federal-register) Source: PRIA, https://policyrisk.com/federal-register/2026-12622 (as of 2026-07-01).